350 related articles for article (PubMed ID: 35144055)
1. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis.
Villacampa G; Tolosa P; Salvador F; Sánchez-Bayona R; Villanueva L; Dienstmann R; Ciruelos E; Pascual T
Cancer Treat Rev; 2022 Mar; 104():102352. PubMed ID: 35144055
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
Liang X; Chen X; Li H; Li Y
Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis.
Xin Y; Shen G; Zheng Y; Guan Y; Huo X; Li J; Ren D; Zhao F; Liu Z; Li Z; Zhao J
BMC Cancer; 2021 Nov; 21(1):1261. PubMed ID: 34814874
[TBL] [Abstract][Full Text] [Related]
4. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
5. Addition of PD-1/PD-L1 inhibitors to chemotherapy for triple-negative breast cancer: a meta-analysis.
Yang J; Liu C; Guo Y; Guo W; Wu X
Front Oncol; 2024; 14():1309677. PubMed ID: 38406799
[TBL] [Abstract][Full Text] [Related]
6. Reconstruction of unreported subgroup survival data with PD-L1-low expression in advanced/metastatic triple-negative breast cancer using innovative KMSubtraction workflow.
Li Y; Liang X; Li H; Chen X
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212119
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
Zhang M; Song J; Yang H; Jin F; Zheng A
Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Sternschuss M; Yerushalmi R; Saleh RR; Amir E; Goldvaser H
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3369-3379. PubMed ID: 33745080
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis.
Khan M; Du K; Ai M; Wang B; Lin J; Ren A; Chen C; Huang Z; Qiu W; Yuan Y; Tian Y
Front Immunol; 2023; 14():1060308. PubMed ID: 36949944
[TBL] [Abstract][Full Text] [Related]
10. Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.
Huo X; Shen G; Liu Z; Liang Y; Li J; Zhao F; Ren D; Zhao J
Crit Rev Oncol Hematol; 2021 Dec; 168():103530. PubMed ID: 34801695
[TBL] [Abstract][Full Text] [Related]
11. Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.
Brito ABC; Camandaroba MPG; de Lima VCC
Thorac Cancer; 2021 Apr; 12(7):1058-1066. PubMed ID: 33586297
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
Front Immunol; 2021; 12():731546. PubMed ID: 34484242
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
Li Y; Xing L; Li F; Liu H; Gan L; Yang D; Wang M; Yin X; Li H; Ren G
Front Oncol; 2021; 11():657634. PubMed ID: 34912699
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
15. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: A systematic review and meta-analysis.
Gao X; Zhu Y; Wang P; Yu L; Ruan S; Shen M; Zhang K
Cancer Med; 2023 Dec; 12(24):21873-21884. PubMed ID: 38063264
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis.
Qi Y; Yan X; Wang C; Cao H; Liu G
Front Pharmacol; 2022; 13():1004821. PubMed ID: 36532783
[No Abstract] [Full Text] [Related]
17. PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis.
Yu Y; Jin X; Zhu X; Xu Y; Si W; Zhao J
Front Immunol; 2023; 14():1206689. PubMed ID: 37377959
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
Cui W; Luo Q; Sun SL; Xu JL; Gu H
Recenti Prog Med; 2022 Dec; 113(12):722-732. PubMed ID: 36420848
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer.
Qi Y; Zhang W; Jiang R; Xu O; Kong X; Zhang L; Fang Y; Wang J; Wang J
Front Pharmacol; 2022; 13():960323. PubMed ID: 36188589
[No Abstract] [Full Text] [Related]
[Next] [New Search]